{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:13Z","timestamp":1787008993728,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["29-shi-1011"],"award-info":[{"award-number":["29-shi-1011"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19fk0310119"],"award-info":[{"award-number":["JP19fk0310119"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B surface antigen (HBsAg) loss is an ideal goal for chronic hepatitis B patients. Antiretroviral therapy (ART) in hepatitis B virus\/human immunodeficiency virus-1 (HBV\/HIV-1)\u2013coinfected patients can lead to hepatic flare (HF) caused by immune reconstitution-induced inflammatory syndrome (IRIS). Here, we investigated the impact of IRIS-HF on HBsAg loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study of 58 HBV\/HIV-1\u2013coinfected subjects HBsAg-positive for \u22656 months before ART initiation and followed for \u22651 year (median 9.9 years) after ART initiation. We examined humoral factors in sera from healthy volunteers, HIV-monoinfected patients, and HBV\/HIV-1\u2013coinfected patients with IRIS-HF or acute hepatitis B infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During ART, HBsAg loss was observed in 20 of 58 HBV\/HIV-1\u2013coinfected patients (34.5%). Of the 58 patients, 15 (25.9%) developed IRIS-HF within 12 months of ART initiation. HBsAg loss was more frequent among patients who developed IRIS-HF (11\/15, 73.3%) than those who did not (9\/43, 20.9%). Multivariate analysis showed IRIS-HF was an independent predictor of subsequent HBsAg loss. Younger age and higher baseline HBV DNA titer were associated with IRIS-HF. Elevation of sCD163, not CXCL9, CXC10, CXCXL11, or CXCL13, was observed at IRIS-HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IRIS-HF was associated with HBsAg loss in HBV\/HIV-1\u2013coinfected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa662","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T07:09:15Z","timestamp":1602832155000},"page":"2080-2089","source":"Crossref","is-referenced-by-count":25,"title":["Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus\/Human Immunodeficiency Virus-1 Coinfected Patients"],"prefix":"10.1093","volume":"223","author":[{"given":"Shiori","family":"Yoshikawa","sequence":"first","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Yoshio","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Yamazoe","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Akita","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Infectious Disease Control and Prevention, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-4051","authenticated-orcid":false,"given":"Junko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Infectious Disease Control and Prevention, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[{"name":"Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"2021061601413702100_CIT0001","author":"World Health Organization"},{"key":"2021061601413702100_CIT0002","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/QAI.0000000000002106","article-title":"Brief report: outcome of acute hepatitis B virus infection in HIV-1-infected patients: possible factors associated with resolution or chronicity","volume":"82","author":"Morsica","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021061601413702100_CIT0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"key":"2021061601413702100_CIT0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/infdis\/jir720","article-title":"Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters","volume":"205","author":"Chun","year":"2012","journal-title":"J Infect Dis"},{"key":"2021061601413702100_CIT0005","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/QAD.0000000000001018","article-title":"Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons","volume":"30","author":"Ryom","year":"2016","journal-title":"AIDS"},{"key":"2021061601413702100_CIT0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/COH.0000000000000327","article-title":"Evolving epidemiology of HIV-associated malignancies","volume":"12","author":"Shiels","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2021061601413702100_CIT0007","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"AIDS"},{"key":"2021061601413702100_CIT0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/jvh.12658","article-title":"More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections","volume":"24","author":"Ding","year":"2017","journal-title":"J Viral Hepat"},{"key":"2021061601413702100_CIT0009","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/cid\/civ421","article-title":"Liver fibrosis by transient elastography and virologic outcomes after introduction of tenofovir in lamivudine-experienced adults with HIV and hepatitis B virus coinfection in Ghana","volume":"61","author":"Stockdale","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021061601413702100_CIT0010","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021061601413702100_CIT0011","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"2021061601413702100_CIT0012","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jvh.12914","article-title":"Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa","volume":"25","author":"Boyd","year":"2018","journal-title":"J Viral Hepat"},{"key":"2021061601413702100_CIT0013","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/infdis\/jiz450","article-title":"High rates of hepatitis B virus (HBV) functional cure among human immunodeficiency virus-HBV coinfected patients on antiretroviral therapy in Zambia","volume":"221","author":"Chihota","year":"2020","journal-title":"J Infect Dis"},{"key":"2021061601413702100_CIT0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/ijmm.IJMM_17_37","article-title":"Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy","volume":"36","author":"Sarkar","year":"2018","journal-title":"Indian J Med Microbiol"},{"key":"2021061601413702100_CIT0015","doi-asserted-by":"crossref","first-page":"e0215464","DOI":"10.1371\/journal.pone.0215464","article-title":"Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV\/HIV co-infection","volume":"14","author":"Gantner","year":"2019","journal-title":"PLoS One"},{"key":"2021061601413702100_CIT0016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12072-019-09953-4","article-title":"Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection","volume":"13","author":"Huang","year":"2019","journal-title":"Hepatol Int"},{"key":"2021061601413702100_CIT0017","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/jvh.13212","article-title":"Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV\/HBV co-infected Chinese","volume":"27","author":"Yang","year":"2020","journal-title":"J Viral Hepat"},{"key":"2021061601413702100_CIT0018","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-6405-9-6","article-title":"Assessment of HBV flare in a randomized clinical trial in HIV\/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand","volume":"9","author":"Avihingsanon","year":"2012","journal-title":"AIDS Res Ther"},{"key":"2021061601413702100_CIT0019","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1086\/597276","article-title":"Immunopathogenesis of hepatic flare in HIV\/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy","volume":"199","author":"Crane","year":"2009","journal-title":"J Infect Dis"},{"key":"2021061601413702100_CIT0020","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/infdis\/jit033","article-title":"Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses","volume":"207","author":"Andrade","year":"2013","journal-title":"J Infect Dis"},{"key":"2021061601413702100_CIT0021","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11904-015-0275-7","article-title":"Emerging challenges in managing hepatitis B in HIV patients","volume":"12","author":"Soriano","year":"2015","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2021061601413702100_CIT0022","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/liv.13716","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int"},{"key":"2021061601413702100_CIT0023","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00535-012-0688-7","article-title":"Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study","volume":"48","author":"Hosaka","year":"2013","journal-title":"J Gastroenterol"},{"key":"2021061601413702100_CIT0024","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5604\/01.3001.0012.7918","article-title":"Immune reconstitution syndrome with initiation of treatment of HBV\/HIV co-infection: activity flare associated with E antigen seroconversion","volume":"18","author":"Rowley","year":"2019","journal-title":"Ann Hepatol"},{"key":"2021061601413702100_CIT0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J Hepatol"},{"key":"2021061601413702100_CIT0026","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1128\/JVI.02277-06","article-title":"Assembly of hepatitis delta virus: particle characterization, including the ability to infect primary human hepatocytes","volume":"81","author":"Gudima","year":"2007","journal-title":"J Virol"},{"key":"2021061601413702100_CIT0027","author":"US Department"},{"key":"2021061601413702100_CIT0028","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2893.2012.01601.x","article-title":"Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients","volume":"19","author":"Kosi","year":"2012","journal-title":"J Viral Hepat"},{"key":"2021061601413702100_CIT0029","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/00002030-199610000-00006","article-title":"Inflammatory cytokines and inhibitors in HIV infection: correlation between interleukin-1 receptor antagonist and weight loss","volume":"10","author":"Rimaniol","year":"1996","journal-title":"AIDS"},{"key":"2021061601413702100_CIT0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/infdis\/jiv123","article-title":"Factors associated with plasma IL-6 levels during HIV infection","volume":"212","author":"Borges","year":"2015","journal-title":"J Infect Dis"},{"key":"2021061601413702100_CIT0031","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/QAD.0b013e328334bddb","article-title":"Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption","volume":"24","author":"Dore","year":"2010","journal-title":"AIDS"},{"key":"2021061601413702100_CIT0032","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2021061601413702100_CIT0033","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/jhep.2001.28459","article-title":"Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?","volume":"34","author":"Nair","year":"2001","journal-title":"Hepatology"},{"key":"2021061601413702100_CIT0034","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1172\/JCI68182","article-title":"Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B","volume":"123","author":"Publicover","year":"2013","journal-title":"J Clin Invest"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa662\/35505947\/jiaa662.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/12\/2080\/38655879\/jiaa662.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/12\/2080\/38655879\/jiaa662.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T21:43:07Z","timestamp":1623793387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/12\/2080\/5929874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,19]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa662","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,15]]},"published":{"date-parts":[[2020,10,19]]}}}